Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 3, 2007

FSMA and Paratek Pharmaceuticals Continue Spinal Muscular Atrophy Partnership

  • Families of Spinal Muscular Atrophy (FSMA) and Paratek Pharmaceuticals extended their R&D collaboration to develop a drug candidate for the treatment of spinal muscular atrophy. 

    The collaboration is focused on optimizing and advancing into the clinic a novel small molecule within Paratek's library derived from the tetracycline class of compounds.

    "We are excited by the progress in our program with Paratek, which in the past year has demonstrated positive results in early cell models of this disease," remarks Kenneth Hobby, executive director of FSMA.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »